Immune Medicine
B-Spinoff of Adaptive Biotechnologies (ADPT) · Biotech · Expected Path by YE 2026
Separates profitable MRD diagnostics (clonoSEQ) from the earlier-stage Immune Medicine drug-discovery platform
Snapshot Across Reports
| Jul 31, 2026 | Jun 30, 2026 | |
|---|---|---|
| Status | Upcoming | Upcoming |
| Investment Grade | B- | B- |
| Revenue | Not disclosed | Not disclosed |
| Expected Date | Path by YE 2026 | Path by YE 2026 |
⚠ Auto-generated profile — not editorially reviewed.
This summary is compiled automatically from our tracked report data. A reviewed in-depth analysis is planned. For further detail ▸ read the Jul 31, 2026 report.